Soligenix’s lead product orBec^® represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal (GI) manifestation of Graft-versus-Host disease GVHD (GVHD), the organ system where GVHD is most frequently encountered and highly problematic. orBec^® is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial for the prevention of acute GVHD after allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens.

The company anticipates completing phase II and releasing news on their findings for orBec’s ability to prevent GVHD by year end.

For more information regarding Soligenix’s current and future operations, visit the full Rodman & Renshaw recap here.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix also expects to begin an NIH-supported Phase 1/2 clinical trial of SGX201 in radiation enteritis in the second half of 2009. Additionally, Soligenix has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix’s lead biodefense product in development is a recombinant subunit vaccine called RiVax(TM) which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax(TM) has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax(TM) will also be the subject of a recent $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.

Technical Chart Analysis

Soligenix’s stock seems to have bounced off the strong $0.18 support level set way back in June. Looking at the 6 month chart, we notice that the RSI still has an oversold representation, recently reaching the 30 point, where there seems to be strong sentiment for a buy signal. The current daily chart seems highly comparable to that of mid September, when the RSI was at a similar point which then bounced upwards to above the 70 line, causing the price to increase from $0.20 to $0.30. We also notice similar volume buys to that of mid September. The MACD and EMA trend lines have entered into the initial stages of a possible golden cross formation. What should be more noticeable for investors is the fact that the golden cross has happened 3 times before during the past 6 months, never failing, thus seems primed to happen once again in the next couple of days. Don’t be too surprised to see the $0.30 resistance being tested once again shortly. For more information on the golden cross formation, visit this link here.

Disclosure: Long SNGX

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Related Posts

• Why Soligenix Will be Successful (OTC:SNGX.OB)
• FDA Play: Soligenix, Poised for a Stellar Comeback (OTC:SNGX.OB)

National Coal Corp. is engaged in mining, processing and selling bituminous steam coal from mines located in East Tennessee and North Alabama and, until March 31, 2008, in Southeast Kentucky. The Company owns the coal mineral rights to approximately 65,000 acres of land and leases the rights to approximately 17,700 additional acres excluding the Southeast Kentucky properties, known as Straight Creek, sold on March 31, 2008. As of December 31, 2008, its mining complexes included three active and two inactive underground mines, one underground mine in the development stage, one inactive and six active surface mines, and one highwall mine. In addition, it had two preparation plants and two unit train loading facilities in Tennessee served by the Norfolk Southern (NS) railroad. It holds seven permits that allow it to open new or re-open existing mines close to its operations. As of December 31, 2008, it controlled approximately 40.8 million estimated recoverable tons of coal reserves.


Recent News Regarding the Coal Industry


Coal prices are indeed destined to go higher as they follow the rise of ‘coal currencies’ such as Australian Dollar (AUD), South African Rand (ZAR) and Columbian Peso (COP). Strong emerging market demand is also pushing up prices although it may be limited by abundant stocks on coal producing countries.

The BofA Merrill Lynch Global Report on energy pointed out that many “oil currencies” including UAE Dirhams (AED) and Saudi Arabian Riyal (SAR) are pegged to the US dollar, but coal exporters tend to keep a free float therefore currencies linked to coal have outperformed both their emerging market and G-10 peers. Source found here


Recent National Coal Corp. Q3 Results


* Third quarter revenues from Tennessee operations increased 19.0% to $22.1million, up from $18.6 million during the
year-ago quarter.

* Tons of coal sold increased 5.9% to 286,447 tons up from 270,515 tons during the year-ago quarter.

* The average price per ton increased 15.2% to $75.00 from $65.08 in the same year-ago quarter.

* For the nine months ended September 30, 2009, net cash flows provided by operating activities improved and are reported
at $6.6 million, versus a negative $3.6 million during the year-ago period.

National Coal Corp. (Nasdaq: NCOC), a Central and Southern Appalachian coal producer, reports that for the three months ended September 30, 2009, it achieved total revenues of $22.1 million based primarily on the sale of 286,447 tons of coal. In the same prior-year period, National Coal generated revenues of $18.6 million primarily through the sale of 270,515 tons of coal. Source found here

Considering they have 40.8 million estimated recoverable tons of coal reserves, these revenues should increase as they further their technological development, and thus achieve a more efficiency.

Technical Chart Analysis

We can see from the chart that the RSI is beginning to what it seems is a rebound, causing an ascention from the 50 on its way to the 70 where it has reached in the $1.3-1.5 range. As well, the MACD and EMA are shaping up for a short-term cross, thus creating a bullish signal. There was a recent sell off post Q3 earnings which should subdue within the next couple of days, and as well there is heavy short interest of 1.57% or 447,300 of the total float with an estimated average of 0.7 days to cover as per shortsqueeze.com’s report. The company also saw its average volume being surpassed today, going from 538,000 to 689,588, an increase of 22%.

MiV Investments Inc. has profiled the company before, to view it please follow this link: http://www.stockshaven.com/bioelectronics-corp-otcbiel-a-doubled-edged-sword/

Recent Company Achievements

*All data and information used is courtesy of BioElectronics Investor Overview

The dermal patch delivery system creates a multitude of new product opportunities for chronic and acute inflammatory conditions. The market potential is estimated at $10 billion or 400 million incidents worldwide. The distinctive value proposition of ActiPatch is the delivery of drug-free therapy that reduces pain and inflammation and accelerates healing by 30% to 50% when compared with the present standard methods of patient care. The current major applications are:

• Medical Surgeries
• Chronic Wounds
• Oral Surgeries
• Sprains and Strains
• Lower Back Pain
• Chronic Repetitive Stress Injuries, Heel Pain, Carpal Tunnel, Bursitis, etc.

Below is a list of the Company’s accomplishments to date.

• United States Food and Drug Administration market clearance
• Canadian market approval for relief of pain in muscosketal complaints in both medical and over-the-counter markets
• CE Mark (European Common Market) Certification for the medical and retail over-the-counter markets
• ISO Certification
• Chosen as “One of 9 Medical Breakthroughs That May Change Your Life” by MedicalHeadway.com
• 15+ domestic independent sales agents
• 20+ International distributors with additional agreements in place or awaiting regulatory approvals
• A medical research agreement with the David Genecov, MD, Dallas Medical Center, a leading medical researcher to supervise and write manuscripts for four studies, plantar fascitis (heel pain), ankle sprains, breast augmentations, and cesarean sections.
• Canadian retail product line launched in June of 2008, actively interviewing distribution partners throughout the rest of the world.
• A solid intellectual property portfolio covering both the product design and the pulse signature.
• A 3-year pipeline of new products for treatment of sports injuries, bone fractures, chronic injuries, chronic wounds, skin conditions, arthritis and post-operative care.
• Product now available online to the consumer market via multiple websites in several countries.
• Projected annual sales in 2008 of over $2,000,000.

Technical Chart Analysis

The RSI has reached nearly a one year low at 33.25, being highly oversold and shorted, and this should overturn soon. MACD and EMA lines have been bilinear for quite sometime, and it is not going to be long before they see a cross, leading to a jump in price as seen in early to mid September. As FDA deadlines near, BIEL should also see a jump in volume, which was down against the average on 11/09/09.

Disclosure: Long NCOC and BIEL

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• Three Valuable Patents, Potential FDA Filing (OTC:PWRM)
• CEO Reaffirms Positive Future Outlook (PINK:SYMW)
• Analyzing Mechanics Behind the Stock Market’s Heart
• The time is now for alternative energy!

(Public, PINK:CDOI.PK)

http://cardio-cor.com/

MiV Investments Inc. has initiated independent research coverage on Cardio Infrared Techs Inc, a company that looks to profit as America’s negative habbits and lifestyles begin to catch up to them. Their phase II Clinical trials are set to be completed by 4Q09, and it couldn’t come at a better time as obesity levels reach new heights. During the past 20 years there has been a dramatic increase in the United States. In 2008, only one state (Colorado) had a prevalence of obesity less than 20%. Thirty-two states had a prevalence equal to or greater than 25%; six of these states (Alabama, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia ) had a prevalence of obesity equal to or greater than 30%. Their lead product, CardioCor, involves fusing a bike and infrared together, in order to create a fat burning oven which trumps anything else in the market. It uses 2800 Watts of Infrared, and thus burns calories up to 10 times faster than that of traditional exercise.

Marketdata projects 6.0% annual growth for the total U.S. weight loss market, to $68.7 billion by 2010, with growth rates for individual market segments ranging from zero to 16% per year.

About Cardio Infrared Technologies, Inc.

Cardio Infrared Technologies, Inc. is a technology and marketing company, which is focused on developing the revolutionary and evolutionary process of combining exercise equipment with medical benefits that go far beyond the normal benefits of standard exercise equipment. Cardio Infrared Technologies, Inc. is committed to continue to market this equipment to the exercise and medical markets and to aggressively expand the market to every country around the world. The equipment has already been featured on “Good Morning America” and “The View.” Cardio Infrared Technologies, Inc. also has an aggressive growth plan that includes acquisitions and development of innovative new equipment and programs in the exercise and medical industries.

CardioCor Product Benefits
Losing weight is synonymous with losing toxins

When your body is overloaded with toxins, whether it is from the contaminants in the food we eat, the air we breathe or the water we drink, your body’s metabolism slows down. This sluggishness and lack of energy causes your body to create more fat cells to store the excess toxins, establishing a vicious cycle that  can help bring to a halt.

Retained toxins are key in the accelerated aging process

The pounds of toxins and waste that overload the elimination systems of the body will cause your body to prematurely age and develop chronic diseases. This is reversible! By applying infrared heat in a controlled environment to the skin, the largest organ of elimination in the body, we can help the body rid itself of poisons and pollutants. It has been recorded that in deep perspiration, the body excretes 85% water and 15% toxic waste.
Live to a ripe old age with energy and vitality

By unburdening your body form the built up toxins and poisons that clog your organs, tissues, blood, muscles, fat and cells, you will also rejuvenate your spiritual and emotional vitality. A cleaner body will engender a livelier spirit and a true love of life well into your older years. Being able to feel alive and vibrant every day is truly a blessing.

A 40-minute session 3 times a week will provide you with:

Sweat Therapy that will increase your calorie burn up to 10 times the normal rate to aid in weight and inch loss. Increased blood circulation, and increased core temperature are key factors in moving the toxins out of your body. Infrared penetrates the body up to 3 inches because the body is 70% water. This fact allows the body to absorb the energy from the infrared as it would absorb the energy of the sun. The absorption of this energy helps to increase the core temperature of the body and the detoxification that it promotes. As a mood booster, infrared can’t be beat. You will enjoy an overall feeling of well-being, starting with your very first session. Light therapy has long been used to aid in depression and respite from the doldrums and gloom of the winter and the effects of SAD.  Increased circulation will help promote collagen production and give you a super deep cleansing effect. You will see a noticeable improvement in skin texture and obvious scars through the use of infrared. Detoxify your body with regular infrared exposure and reap the benefits of natural good health.  Natural therapists confirm that sweating is a great way to remove toxins, using infrared heat offers this benefit at a comfortable temperature.?Infrared has been documented as aiding in the pain management and recuperation of sports injuries, arthritis and more.

Key Weight Loss Market Statistics

• Marketdata estimates that the total U.S. weight loss market was worth $55.4 billion in 2006. The market should reach $58.7 billion this year and $68.7 bill. by 2010 (see attachment, table).

• Retail meal replacements were hit hard by the low-carb craze, but have shown signs of growing once again. We estimate that sales were $1.17 billion in 2006.

• OTC diet pills market is in turmoil as the FTC fines marketers $25 million and many brands fight for market share and tinker with non-ephedra ingredients.

• In 2006, 68% of dieters preferred a diet program they could access from home/online/by phone, and 56% want a plan based on regular (not diet) food.

• Bariatric surgeries reached record levels of 177,000 in 2006, representing a $4.4 billion market. However, major insurers still don’t cover these surgeries and growth slowed to only 4%. More obese Americans are having the procedure done in Latin America, where the cost is substantially less.

• Diet food home delivery grows into an $800 million market segment, fueled by NutriSystem, Jenny Direct, Medifast and a few dozen others. Not all companies provide national delivery. Many only cater to local markets in Los Angeles, Chicago or New York, delivering premium priced gourmet fresh food. The average monthly cost for consumers is $725.

• Diet soft drinks Diet sodas’ share of all soft drinks has risen to 29.5%, almost the historical peak, and this is forecast to rise to 31%. This segment was worth $19 billion in 2006.

• Diet drugs The prescription $459 million diet drugs market did grow somewhat in 2006, but still awaits the FDA’s approval of Rimonabant (Acomplia).

• Market leaders Weight Watchers ($1.2 bill.), NutriSystem ($568 mill.), LA Weight Loss ($500 mill.), Jenny Craig ($462 mill.), Slim-Fast ($310 mill.), Herbalife ($271 mill. ” U.S. diet prods. sales).

Experienced Management

Wayne K. Bailey, CEO

Wayne has spent his life as a CEO and CFO of various corporations, both private and public that had a competitive edge over the competition.  Wayne spent 3 years as the CFO of a Publicly traded mortgage bank.  For 12 years Wayne was part of a group that acquired manufacturing companies in the Aerospace, water, wood, steel, plastic, circuit board and other manufacturing and distribution business. In the mid 1970’s Wayne founded and was the CEO of a private plastic company that developed the process to thermoform PET plastic and became part of the development group of Eastman Chemical for PET products.
A decade ago, Wayne fought hard against the established medical protocol of the day as he lost the battle to save his daughter from small cell ovarian cancer and to institute a more holistic, direct and focused methodology to bring his daughter back. As expected, his input was rejected as the time, but is now one of the accepted treatments for this dreadful, fateful disease. As a result, over the last decade, Wayne has focused his energies toward educating his friends and associates toward a more holistic, healthy lifestyle through nutritional supplements and detoxification. It is as a result of this quest that Wayne decided to bring the CardioCor to the U.S. and begin the process of teaching people the overall dangers of the toxins in our environment and how to safely remove them.

Elle Reinhardt, M.B.A., T.N.D.

Elle’s background includes her early years as an educator and encompasses a career in interior design and construction before her inevitable confrontation with the allopathic medical community several years ago. After a year and a half of remaining undiagnosed for a medical problem by her doctors, Elle diagnosed herself through a serendipitous newspaper article and the internet. She then proceeded to heal herself and return to school to achieve her Doctorate in Naturopathy at Clayton College of Natural Health, Birmingham, AL.
She has focused the rest of her life towards educating others as to the ways of achieving and maintaining homeostasis. Her passion and focus are education through whole food nutrition, cleansing and detoxification to aid her clients in achieving a vibrant longevity. Elle is also a Board Certified Reflexologist.  Elle joined forces with Wayne Bailey in the CardioCor endeavor to bring to America the gift of a focused cardio-infrared program that is unlike anything available in the United States today.

CAROL ANGLIN, NATIONAL SALES DIRECTOR

Carol joined the Cardio-Cor team in November 2006.  Carol started working with Cardio Infrared Technologies, Inc doing cold calls in the Utah market. Carol quickly completed sales of two units by the end of 2006. In 2007 she was doing cold calls on a nationwide basis developing sales leads and sales first on the East Coast and then on the West Coast. Carol has become a very valuable member of the Cardio-Cor  sales and management team.   The training she has received and the first hand observations of the results obtained by the people using the Cardio-Cor has given her a unique perspective that has added to the mounting sales momentum of Cardio Infrared Technologies, Inc. Carol was part of the team that attended the Anti-Aging show in December 2007 and was given the responsibility for the sales leads generated from that show and most of the leads generated from the other shows in 2007. Carol has aggressively followed up on the leads generated by these shows, which as resulted in many sales that may have been missed if not for her diligence. Carol Anglin comes to Cardio Infrared Technologies, Inc. with over 25 years of sales experience which includes selling photography, Tanning equipment and Time Shares.  Carol has won several awards in the Time Share industry for most valuable employee and for record numbers of leads generated. Carol comes to Cardio Infrared Technologies, Inc. from a desire to help people gain a healthier more natural way of improving their bodies.  Carol’s son Scott died of bone cancer at age 20 which led her to a quest to find other alternative ways to keep the body in a natural healthy state of being.”

Refocusing the Company

The company first brought the Unit to the United States two years ago under the name Cellubike, so named by the Italian manufactures, which only recognized the beauty benefits of the Bike. Over the past 40 years, the intrinsic value of Infrared has blossomed into a multi-billion dollar beauty industry in Europe, where, typically, most beauty innovations are discovered. As our knowledge and experience with this amazing product grew, our clients and we quickly realized that the results being experienced were nothing short of astounding. Yes, the beauty benefits were still there such as weight loss, inch loss, diminishing of cellulite, and building of collagen in the skin. But, just as importantly, the body was detoxifying and promoting even better results through loss of toxins. Many clients experienced the reduction, if not total disappearance, of chronic conditions such as fibromyalgia, arthritis, colitis, bursitis and pain from sports injuries that had plagued them for years as you can read in the Testimonials. Others were surprised as scars diminished, recovery from strokes was accelerated and eczema conditions were relieved. With this exciting new information we felt it was imperative to relaunch this amazing device in a new light. We found it fitting that the new name incorporates all aspects of its capabilities, thus highlighting the medical benefits. Hence the CardioCor emerged, reflecting not only the Cardio benefits, but also, the benefits of increasing the body’s core temperature and boosting the client’s metabolism!

Company News

Cardio Cor Announces $400K in New Orders for Cardio Cor and Cardio Cor II^TM

LAS VEGAS, NV–(Marketwire – October 30, 2009) – Cardio Infrared Technologies, Inc. ( PINKSHEETS: CDOI) www.cardio-cor.com, a leading Health and Wellness technology and marketing company, announced today that it has received orders from a new Florida-based client for two of the Commercial Cardio Cor bikes and six Personal Cardio Cor II™ bikes.

Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc., stated: “A new customer in Florida has ordered two Cardio Cor units for immediate delivery and six Cardio Cor II units for delivery as soon as they are available in first quarter 2010. The sales revenue of this order exceeds $100,000. We have also taken orders from customers in San Francisco, CA, Palm Springs, CA, Hollywood, CA, Palm Beach, FL, New York, NY, Salt Lake City, UT, Atlanta, GA and Atlantic City, New Jersey for the new Cardio Cor II™. The orders placed now total well over $300,000. It is understood that additional orders will be received soon and will result in the new production capacity being sold out for the first three months of 2010 production. Additional demand for the Cardio Cor II™ will be generated at the “Anti Aging Show “coming in Las Vegas mid December.”
New customers are being told to get their orders in now or they will be on a waiting list that takes them to mid year 2010.

Cardio Infrared Tech Announces New Infrared Lights for the Cardio-Cor II

LAS VEGAS, NV–(Marketwire – October 21, 2009) – Cardio Infrared Technologies, Inc. ( PINKSHEETS: CDOI) www.cardio-cor.com, a leading Health and Wellness technology and marketing company, announced today newly developed infrared lights for the Cardio-Cor II personal Exercycle.

Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc., stated: “The new infrared lights will now power the Cardio-Cor II. The new lights were developed specifically for Cardio Infrared Technologies and the new Cardio-Cor II personal Exercycle. The new lights are the product of recent innovation in bulb design and technology that provide for a smaller bulb but retains all the benefits of the previous larger bulb. The new 100-watt bulb is only one inch in diameter and four inches long and is extremely energy efficient. The older bulbs are five inches in length and five inches in diameter. The light array in the Cardio-Cor II is now only two inches thick instead of the nine inches as on the original Cardio-Cor. This innovation allows for a much smaller, super compact Exercycle. Cardio Infrared Technologies, Inc. will use the new lights in all new products. These new lights will allow Cardio-Cor to develop a wide range of compact products that couple the use of infrared and exercise. Cardio Infrared Tech remains committed to develop and/or acquire improved infrared technologies for the benefits of our customers and stockholders.”
The new personal Cardio-Cor II Exercycle is being well received in all beta market tests and is expected to dramatically improve sales in 2010.

Cardio Infrared Technologies, Inc. Announces Reduction in the Amount of Authorized Stock

HENDERSON, NV–(Marketwire – 10/23/09) – Cardio Infrared Technologies, Inc. (Pinksheets:CDOI – News) (www.cardio-cor.com) today announced that its Board of Directors has authorized a reduction of the authorized shares from 5,000,000 to 1,500,000.
“The Board took the action to reduce the amount of authorized stock to more accurately reflect the capitalization of the company. This lower authorized is a one third reduction in the authorized shares for the company. The board believes that this reduction in authorized shares will facilitate the company’s ability to attract companies for acquisition and expansions. The company currently has 47,181,495 shares issued with 4,714,172 free trading shares currently issued and outstanding,” said Wayne Bailey, Chief Executive Officer of Cardio Infrared Technologies, Inc. “We continue to pursue our acquisition and growth plan and believe this 1/3 drop in authorized will facilitate our financial plans for the company.”

Cardio Infrared Phase II Clinical Trials to be Completed This Year

LAS VEGAS, Oct. 5, 2009 (GLOBE NEWSWIRE) — Cardio Infrared Technologies, Inc. (Pink Sheets:CDOI – News) (www.cardio-cor.com), a leading Health and Wellness technology and marketing company, announced today that the clinical trials being conducted in Pennsylvania completed Phase I earlier this year and demonstrated the efficacy portion of the trials. Phase II, which has been underway for 6 months, has been testing the effects on Detoxification and will be available by the end of this year.

Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc., stated: “The second phase of the clinical trials are within two months of completion. The expanded number of people involved in the second phase is providing a tremendous amount of additional information and data on the Cardio-Cor system. The results from the expanded Phase II are reported to be superior to those released in the first phase and additional levels of study are showing amazing results according to the community of patients involved. The expanded basis of the second phase of the study is concerned not only with weight and inch loss but also on detoxification and the tested results of infrared on the body. The report on the second phase is scheduled to be completed before the Las Vegas Anti-Aging show in December. The third phase of the Clinicals will be a comparison of the Cardio-Cor ExerBike vs. a treadmill which will document the additional benefits of using the Cardio-Cor over any other type of exercise equipment available to the public.”

The clinical trials that were completed in Italy will also be released within the next three months. The Clinicals from Italy were completed using Italian guidelines, not FDA standards. They show vast weight, inch and cellulite loss. They also address detoxification and many of the other issues that our Phase II study is now addressing. The release of the additional studies will add validity to the technology and products of Cardio Infrared Technologies.

Disclosure: Long CDOI

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• Congratulations to everyone for big gains!
• Holiday Season May Bring Renewed Interest in BizAuctions (OTC:BZCN.PK)
• Giving Birth to a Profitable Company (OTC:IVOB)
• Three Blockbuster Drugs Seeking NDA (AMEX:AEN)

(Public, OTC:ACTC.OB)

MiV Investments Inc. has initiated independent research coverage on Advanced Cell Technology Inc. (OTC:ACTC.OB), which is anticipating a filing of an investigational new drug (IND) application which takes on a 28B Age-related macular degeneration (AMD) market, with over 30 million people affected by the disease. The company expects to file the IND prior to the end of Q409. Macular degeneration is a medical condition usually of older adults that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in “dry” and “wet” forms. It is a major cause of visual impairment in the elderly (>50 years). Macular degeneration can make it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life. There is no other existing therapeutic treatments which regenrate the lost cells, leaving 90% of Age-related macular degeneration (AMD) patients with dry variety as an unmet need. This condition affects more than 15% of elders aged 75 and above, leaving it as one of the top threats to an elder’s health. The company has also taken major strides, recently moving from the PINK sheets, to the OTC bulletin and sufficing the qualifications needed to be pink sheets compliant. Technicals on the company’s stock have also been highly bullish as of late, sitting at a nine month price low, all the while anticipating news on what could be the beginning of a revolutionary new drug.

The company is in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. The Company noted that in the next few weeks, it will be completing the preclinical work necessary for filing the IND. To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year.   “We are very pleased with the long-term safety and efficacy data,” said Dr. Robert Lanza, ACT’s Chief Scientific Officer. “We have carried out pre-clinical studies using these cells in multiple animal models, and to-date have not seen any teratoma formation or untoward pathological reactions. We are optimistic that human embryonic stem cells (hESCs) will serve as a potentially safe and inexhaustible source of RPE for the treatment of a range of macular degenerative diseases.”   Existing therapies only treat the condition and do not regenerate cells of the macula that have been damaged. Plus, existing therapies only treat wet AMD, not dry AMD, leaving a significant unmet need for an effective treatment for the 90% of AMD patients who have the dry variety. The company expects to file an IND for its RPE program by end of 2009.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

Worldwide Recognition

Dr. Robert Lanza, its Chief Scientific Officer, was featured on Deepak Chopra’s Wellness XM Radio and Barbara Walters 20/20 special.  The shows focused on Dr. Lanza’s research at ACTC and his new book “Biocentrism.”  SIRIUS XM Stars Channel is the flagship satellite talk station featuring unique and diverse programs, including Deepak Chopra and broadcasting legend Barbara Walters, among others. It has a listenership of approximately 9 million people.

Chopra is a prolific author of over fifty-five books on topics ranging from health to consciousness and quantum mechanics, and was heralded by Time Magazine as one of the top heroes and icons of the century.  On his show, Lanza discusses the cutting edge of regenerative medicine, including ACTC’s efforts to use stem cells to treat blindness, vascular damage, and heart disease.  ACTC hopes to file at least one application with the FDA this year to begin human clinical trials using retinal pigment epithelium (RPE) cells to treat macular degeneration and other retinal degenerative diseases.

Lanza and Chopra also discuss “Biocentrism,” and how life and consciousness are the keys to understanding the true nature of the universe.   “We think life is an accident of physics,” explains Lanza.  “But a long list of experiments suggests just the opposite.  Amazingly, if you add life to the
equation, you can explain some of the biggest puzzles of science. ”

Deepak Chopra stated, “Having interviewed some of the most brilliant minds in the scientific world, I found Dr. Robert Lanza’s insights into the nature of consciousness original and exciting.  His theory of biocentrism is consistent with the most ancient wisdom traditions of the world which says that consciousness conceives, governs, and becomes a physical world.  It is the ground of our Being in which both subjective and objective reality come into existence.  I hope to have Dr. Lanza continue this conversation on Sirius XM satellite radio in the future.”

“We believe that Dr. Lanza has contributed significantly to the understanding of the key role stem cells play in the field of regenerative medicine,” said William M. Caldwell IV, Chairman and CEO of ACTC.  “Through his scientific leadership the field is on the verge of therapeutically validating a new platform for regenerative medicine.” Source found here

Retinal Pigmented Epithelial Cell Program

Advanced Cell Technology is currently focused on using its proprietary technologies to generate stable cell lines including retinal pigment epithelium (RPE) cells for the treatment of diseases of the eye, including macular degeneration, which represents a $28 billion dollar market. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 years of age in the United States. AMD is a disorder that affects the macula of the eye that causes decreased visual acuity and possible loss of central vision. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 years of age have the condition.

Positive Clinical Trials

ACT demonstrated the ability to rescue visual function in rats through implantations of RPE cells derived from human embryonic stem cells. In collaboration with Raymond Lund at the University of Utah, the company performed RPE transplantation into sub-retinal space of rats that naturally become blind in several weeks due to RPE degeneration and photoreceptor death. In the experiments conducted by the company, the rats were injected with embryonic stem-RPE cells into the sub-retinal space of the eye at 21 days after their birth — an age at which photoreceptor degeneration has not yet occurred. As control measures, some rats received injections of cell culture medium alone or were not injected at all. Subsequently, tests for visual function were performed at 60 and 90 days after birth — times at which loss of photoreceptor cell has produced characteristic vision deficits. The results represented a major breakthrough. The injected RPE cells grew normally without forming teratomas. Soon, the rats were able to follow lights with their eyes and attained approximately 70% of the spatial acuity of a normal, healthy rat. Necropsy revealed that the eyes had grown layers of the retinal cells. The experiment demonstrated that animals receiving the human embryonic stem cell-derived RPE cells performed significantly better than medium-only treated (50% improvement), or untreated (100% improvement) controls in visual performance. In addition, the human embryonic stem cell-derived RPE cells did not appear to cause any side effects in the animals. The research was published in Cloning and Stem Cells and was also referenced in Scientific American. Source found here

Understanding Advanced Cell’s Position

Market Opportunity: Age related macular degeneration (AMD) represents a “tremendous” market opportunity given the size of the patient population and the lack of treatment alternatives. Diseases of the eye affect more than 30 M people worldwide and represent a $20+B market.

• Existing therapies only treat the condition and are not curative but palliative and do not regenerate cells of the macula that have been damaged.  Additionally, existing therapies only treat Wet AMD not Dry AMD hence leaving a significant unmet need for an effective treatment for the 90% of AMD patients who have the dry variety,

• AMD is a common eye disease that leads to deterioration of the macula which is the central area of the retina in the back of the eye, the paper-thin tissue where light-sensitive cells send visual signals to the brain.  In particular, sharp, clear, “straight ahead” vision is processed by the macula.  Injury to the macula results in the formation of blind spots and blurred or distorted vision.  When the macula becomes damaged, many daily activities such as driving and reading become increasingly difficulty,

• AMD most often affects individuals over 50 years of age.  There are two forms of macular degeneration: dry macular degeneration or wet macular degeneration.  Dry AMD takes place when the light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.  As dry AMD gets worse, the patient may see a blurred spot in the center of their vision.  As the disorder progresses, and less of the macula functions, central vision is gradually lost in the affected eye.  The most common symptom of dry AMD is slightly blurred vision.  The affected individual may need more light for reading and other tasks,

Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula.  As the dry form worsens, some people begin to have abnormal blood vessels growing behind the macula.  These new blood vessels tend to be very fragile and often leak blood and fluid (hence ‘wet’ macular degeneration).  The blood and fluid raise the macula from its normal place at the back of the eye.  Damage to the macula occurs rapidly.  With wet AMD, loss of central vision can occur quickly.  Wet AMD is also known as advanced AMD.  It does not have stages like dry AMD.  The wet form is diagnosed in approximately 10 percent of cases; however, it results in 90% of the visual impairment and is considered advanced AMD (there is no early or intermediate stage of wet AMD).  Wet AMD is always preceded by the dry form of the disease.

Investment Highlights

• Currently ACT is finalizing preclinical studies for the bio-distribution of our therapeutic program addressing Retinal Degeneration (i.e. AMD or macular degeneration in the eye) and has completed GLP Safety Studies and long-term efficacy studies for the RPE therapy with positive results.

• The Company expects spiking studies for the RPE product to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of 2009.

• Working on acquiring funding for Phase II clinical trials for the Company’s Myoblast program, an autologous (meaning “one’s own”) adult stem cell therapy for treating cardiac disease. Historically the Myoblast program successfully completed several Phase I clinical trials.

• Published positive results from HG program demonstrating hemangioblasts’ ability to repair vascular damage in animals. Therapy could be effective for treatment of blood and cardiovascular diseases. Anticipates filing an IND in 2010.

• Made progress in macular degeneration indication by reporting positive data for RPE cell animal study. Entered into collaboration with Casey Eye Institute for preclinical trials. Completed Pre-IND meeting with FDA. Expects to file IND in 2009.

• Developed and demonstrated technique to generate embryonic stems that maintain developmental potential of the embryo and therefore has potential to shift the ethical debate. Announced hESC lines created without destroying an embryo in multiple studies.

• Owns or licenses over 380 patents and patent applications related to stem cell therapy.

• Large Target Market: Regenerative Medicine has potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others.

• Led by experienced management team and scientific experts including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger Gay PhD and Director of Operations Rita Parker.

Growing Legislative Support

• CA Prop. 71 provides $3.0 billion in funding over 10 years for stem cell research, with preference given to research that is ineligible for NIH funding.

• Other states (e.g., NJ, CT, FL, IL, MD, NY, MA, and MO) have passed or proposed similar initiatives.

• Political landscape moving in positive direction for stem cell industry starting with President Obama new embryonic stem cell directive initiated January 2009. Source found here

FDA News

*Information via BioMedReports’ FDA Calendar

Highly Experienced Leadership

Read this article regarding ACTC’s Chief Scientific Officer within Discover Magazine.

“Whether defying the dean of the University of Pennsylvania Schl. of Medicine so he could publish a book on world health or challenging the titans of cosmology, Robert Lanza has never followed the script. It’s no wonder, then, that this renegade doctor would lead the charge into medicine’s most controversial turf: the creation of cloned embryos for therapy and the engineering of spare human parts.”

William M. Caldwell, IV

Chairman and CEO

Mr. William Caldwell serves as Chairman and Chief Executive Officer of the Company and has a 30-year management career working with emerging technologies and restructuring distressed corporate environments. During his career, he has served in senior executive positions both in marketing and finance. He has worked with Booz Allen and Hamilton; the Flying Tiger Line Inc.; Van Vorst Industries; and Kidder Peabody. He started a firm specializing in corporate financial and strategy planning, which was instrumental in restructuring over $1.0 billion of debt for over twenty companies and partnerships. He was a pioneer in the satellite radio auctions as president of Digital Satellite Broadcasting Corporation; assisted in the financing, and became president and ultimately CEO in the restructuring of CAIS Internet. He has advised corporations, both public and private, in technology, telecommunications, retailing, real estate, hospitality, publishing, and transportation. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton Graduate School of Finance. He serves as a director of Lee Pharmaceuticals (LPHM.PK) and King Koil Franchising Corp.

Robert Lanza, M.D.

Chief Scientific Officer

Dr. Lanza joined ACT in 1999. Dr. Lanza has over 25 years of research and industrial experience in the area of stem cells and regenerative medicine. From 1990 to 1998, he was Director of Transplantation Biology at BioHybrid Technologies, Inc., and is currently an Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine. He has several hundred scientific publications and patents, and has authored/edited 20 books, including the “Handbook of Stem Cells” (as Editor-in-Chief), Principles of Tissue Engineering, XENO, the Yearbook of Cell & Tissue Transplantation, and One World: The Health & Survival of the Human Species in the 21st Century (as editor, with forewords by C. Everett Koop and former President Jimmy Carter). He is a former Fulbright Scholar, and studied as a student in the laboratory of Richard Hynes (MIT), Jonas Salk (The Salk Institute), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. Degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.

Vice President of Regulatory

Mr. Mickunas, a recent addition to the ACT team, is the Company’s Vice President of Regulatory. Mr. Mickunas is in charge of spearheading the company’s effort to translate its cutting edge research into FDA approved therapies ready for clinical trials. Mr. Mickunas is working with Dr. Robert Lanza and ACT’s Development Team to finalize and submit the IND for the RPE program to the FDA. Mr. Mickunas brings 28 years of experience from a number of disciplines including biotechnology, medical device and pharmaceuticals. He has worked in preclinical program development, clinical affairs, regulatory affairs/compliance and quality assurance, and has worked closely with all disciplines involved in product development. Prior to joining Advanced Cell, Mr. Mickunas was Executive Director, Regulatory Affairs and Quality Assurance for Applied Genetic Technologies Corporation, a privately held gene therapy and genomics-focused biotech company. Mr. Mickunas was previously Senior Director of Regulatory Affairs and Compliance for Control Delivery Systems, Inc., where he managed the submissions of IND filings, among other responsibilities. He also held senior regulatory positions at Bioheart, Inc., Cytomed and Del Laboratories. He received his B.S. and pursued graduate studies in human biochemistry at Fairleigh Dickinson University, as well as a Masters Degree from Fairfield University.

Senior Director of Manufacturing

Dr. Gay serves as Advanced Cell’s Senior Director of Manufacturing. Dr. Gay is responsible for Process Development and Clinical Manufacturing at Advanced Cell. For the past 28 years, he has been involved in clinical manufacturing and product development at a number of biotechnology companies specializing in cell-based products and services including Organogenesis, Diacrin, Genvec and Mytogen. He has extensive experience directing and leading product development and clinical trial manufacturing for cellular products having planned and executed R&D programs leading to market introduction of first-ever products for two biotechnology companies prior to joining Advanced Cell. He received a Ph.D. in biochemistry from the University of Rochester in 1980 and was a post-doctoral fellow at Harvard Medical School.

Director of Operations

With Advanced Cell since 2005, Ms. Parker brings a 20 year career in management to her role as the Company’s Director of Operations. A native of Massachusetts, she has held senior positions in marketing and operational management, focusing on paving the way for local businesses to expand their geographical footprint and increasing their technological and productive capabilities by introducing new and efficient information technology products and systems; a few of these companies include Digital Equipment Corporation, Computer Devices, and Banyan Systems, Inc.

External News Affecting Advanced Cell

Judge Throws Out Stem Cell Lawsuit

by Jocelyn Kaiser

A federal judge has rejected a lawsuit challenging the Obama Administration’s policy lifting restrictions on using federal funds to study human embryonic stem cells. Christian groups had sued the National Institutes of Health in August, arguing on behalf of themselves and embryos that NIH’s stem cell guidelines violate a ban on using federal funds to create or destroy human embryos. According to Bloomberg,  U.S. District Court Judge Royce Lamberth ruled yesterday in Washington, D.C., that the groups had no standing because the U.S. Supreme Court has found that embryos are not persons under the law, and the unborn have no constitutional right to life. The AP’s story says the judge also rejected the argument that the guidelines would reduce the number of embryos available for adoption. http://blogs.sciencemag.org/scienceinsider/2009/10/judge-throws-ou.html

Recent Company News

Advanced Cell Technology, Inc.’s Shares To Trade On Over-the-Counter Bulletin Board
Tuesday, 6 Oct 2009 07:40am EDT

Advanced Cell Technology, Inc. announced that effective immediately the Company’s shares will be traded on the Over-the-Counter Bulletin Board under its previous ticker symbol ACTC. The Company is now fully reporting and up-to-date with all of its filing requirements. The Company`s stock had previously traded on the Pink Sheets.

Advanced Cell Technology, Inc. Completing Pre-Clinical Activities In Preparation For IND Filing
Tuesday, 22 Sep 2009 11:28am EDT

Advanced Cell Technology, Inc. announced an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. In the next few weeks, the Company will be completing the preclinical work necessary for filing the IND. To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year.

Advanced Cell Technology, Inc. and Collaborators At The Casey Eye Institute Present Promising Data Supporting Safety and Efficacy of Stem Cell Therapy to Combat Retinal Disease
Friday, 12 Jun 2009 09:39am EDT

Advanced Cell Technology, Inc. and its collaborators at OHSU reported the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset blindness. The research, which appears online ahead of print in the journal Stem Cells, shows long-term functional rescue using hESC-derived cells in both the RCS rat and Elov14 mouse, animal models of retinal degeneration and Stargardt, respectively. The cells survived transplantation for prolonged periods (>220 days) and sustained visual function without tumor formation or untoward pathological reactions. Near-normal functional rescue was also achieved in the `Stargardt` mouse. To further address safety concerns, a study was carried out in the NIH III immune deficient mouse model. Long-term data (spanning the life of the animals) revealed no evidence of tumor formation after transplantation.

Advanced Cell Technology, Inc. Prepares IND Filing with the Capability to Produce Stem Cell Lines without the Destruction of the Embryo
Thursday, 12 Mar 2009 08:00am EDT

Advanced Cell Technology, Inc. announced that it is finalizing preparations to file an IND in the second half of this year with the Food and Drug Administration for the Company’s retinal pigment epithelium (RPE) cell program for the treatment of diseases of the eye. It has available the only technology that can today produce stem cell lines without the destruction of the embryo. While President Obama recently issued an Executive Order that authorizes expanded federal funding for research using stem cells produced by destroying human embryos, the decision remains controversial as some believe that the Government should not fund the ongoing destruction of human embryos. In the coming months Congress will be debating altering or eliminating the Dickey Wicker Amendment which is at the core of this controversy. Advanced Cell Technology`s stem cell platform offers a compromise on this issue, as described in peer review scientific journals published over the past several years. Over 3000 healthy children have undergone the medical procedure, PGD, which is at the core of ACTC`s technology.

Overall Sentiment & Technical Analysis ( Click chart to enlarge )

For the past six months, ACTC has moved within a very dependable price channel shown in Blue lines on the chart.  The channel was defined by a 193% gain in price back in May to June of this year.  Since then, the price has been waiting for the bottom trend-line of the price channel to catch up (consolidation). It appears this has finally happened. The stock has found the bottom trend-line of the channel where the big move back in May started.  That move started with a run in price that quickly made it to the middle trend-line (dashed Blue line) around .18 cents. The conditions are classically bullish as the daily 100 SMA (Orange line) is above the 200 SMA (Yellow line).  As the buyers assume control of this stock, the price should easily find the 100 SMA around .15 cents.  With growing volume (gray bars), the stock could quickly move back to the middle trend-line and likely back up into the upper half of the price channel.  Of course, news can trump everything and any FDA action would probably send this stock well above the top trend-line. It’s good to keep in the back of your mind that the price has already tested the top trend-line twice this year and we have seen numerous times that the third time is the charm to finally break out.

Disclosure: Long ACTC

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• Are you feeling the sugar high yet?
• Why MuGard Will Be Successful
• Hot FDA Trade: BioDelivery Sciences International
• The importance of RSI Chart [VIDEO]

(PINK:WTWO.PK)

MiV Investments initiates an independent company profile on W2 Energy, Inc. (PINK:WTWO.PK), which looks to breakthrough within a $23B bio-fuel industry, as a successful alternative renewable energy company amongst worldwide rising oil and energy prices. since the dawn of technological advancements, the world has relied on the burning of fossil fuels in order to generate sufficiency and reliability for our energy needs. Most fossil fuels are formed from the remains of long-dead creatures and plants. Buried over the course of hundreds of millions of years, these carbon-based deposits have been converted by heat and pressure over time into such combustible substances as crude oil, coal, natural gas, oil shales and tar sands. While this has proven to be a cost effective method within the short-run, at current rates, the world uses fossil fuels 100,000 times faster than they can form. The time for alternative renewable energy to emerge from its shackles as a viable and feasible source has long been overdue. World oil demand is set to rise in 2010, as the price per barrel should see $80. Furthermore, the Minister for Natural Resources, Mines and Energy Stephen Robertson has been advised by the independent Queensland Competition Authority (QCA) of their decision to increase electricity prices by 11.82% for the 2009/10 financial year. The reason oil prices would likely rise in early 2010, is due to the outlined production cuts by the OPEC crude producers’ cartel since last year. OPEC members, which pump 40 per cent of the world’s oil, agreed in late 2008 to remove a massive 4.2 million barrels of daily output from the market as it sought to prop up crumbling prices. The cartel’s official daily output quota has stood at 24.84 million barrels per day since January but analysts say that compliance with the cuts has slipped over recent months to less than 70 per cent. Amongst these difficulties, lies the opportunities for W2 Energy, as it has the ability convert the syngas into hydrocarbon liquids (ultra low sulfer diesel, JP8 jet fuel, and/or gasoline). According to David Freund, Vice-President of Business Development, they have been developing this technology for over 9 years and now feel it is the optimal time to let it shine for the rest of the world to witness.

Currently, bio-fuels are capturing about $23 billion of the $1.3 trillion spent each year to power our cars, trucks, airplanes, trains and ships. That’s just two percent of the market with an astounding 98 percent upside. One Brazilian company planning to spend $54 billion on this new fuel by 2010, estimating that the bio-fuel market is set to grow by an estimated 1000%.

About W2 Energy, Inc.

W2 Energy designs mass-to-energy plants which convert feedstocks into syngas, using patented low temperature highly efficient non-thermal plasma-based reactor technology. This allows the plant to run at a low cost and a profit.

• coal
• battery waste
  
• municipal solid waste
• agricultural waste
• human and animal waste
• tires and plastics
• medical waste

Random Posts

• 10 Easy Tips to Foster a Successful Investment Portfolio
• CDE is a buy
• NSPT is a buy
• Investing in Gold – Better than Many Kinds of Savings Accounts

BioCurex Inc

(Public, OTC:BOCX)
http://www.biocurex.com/

BioCurex, Inc. (“BioCurex” or “the Company”) is a biotechnology company developing products for cancerdiagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by 2009. The Company uses a novel, patented technology based on the RECAF™ cancer marker, discovered by Dr. Ricardo Moro-Vidal, BioCurex’s chief executive officer (CEO), president, and founder. RECAF™ is a molecule found on malignant† cells but absent from most normal or benign cells. BioCurex believes that the detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and imaging techniques. The RECAF™ marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF™ is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers. The Company’s RECAF™ technology is reported to have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF™ recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate specific antigen (PSA) test. A RECAF™-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex’s aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF™ technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.

The current state of cancer detection

• According to the World Health Organization, the number of people diagnosed with malignant tumors will increase by 50% in a dozen years.

• Survival rates depend mostly on how early the disease is discovered. i.e. The five-year survival rate for breast
cancer ranges from 87% at Stage I to only 13% at Stage IV.) RECAF technology detects malignancy earlier, more accurately, and potentially far more cost-effectively.

• Current cancer detection is still primitive. Needle and surgical biopsies are the most accurate, but far from
perfect. They’re also highly intrusive and can cause serious infections. Blood testing, as it now exists, is much less accurate and rife with false positives. (i.e. PSA is a mediocre marker for prostate cancer. It catches only 80% of malignancies — yet produces 65% false positives in patients with benign tumors that usually require no treatment. Yet, all too often, patients are still subjected to costly and debilitating surgical procedures.)

Pipeline

Effectiveness of BioCurex’s RECAF

Other Currently Available Cancer Makers

Key Points

BioCurex maintains semi-exclusive license agreements with Abbott Laboratories (ABT-NYSE) and Inverness Medical Innovations, Inc. (IMA-AMEX) to commercialize products using RECAF™ technology. These licenses benefit BioCurex through the payment of milestone fees and royalties, as well as by giving the Company access to independent diagnostic expertise and validation of RECAF™.

The Company has developed two diagnostic kits that identify cancerous tissue versus normal or benigntissue by targeting RECAF™:
(1) Histo-RECAF™ (approved in the U.S. as a Class I Medical Device); and (2) Cryo-RECAF™. The Company is also finalizing Serum-RECAF™, an assay to detect RECAF™ levels in a patient’s blood. Other product areas include tumor imaging and the development of a Rapid Test for initial point-of-care cancer detection.

As of 2005, global laboratory diagnostic tests exceeded $25 billion each year, with molecular diagnostictesting growing by roughly 20% annually and estimated to be over $5 billion by 2009. In the diagnostics market, cancer testing, which is dominated by serum-based cancer markers, recently exceeded $2 billion and is expected to experience some of the greatest growth over the next three to five years.

BioCurex’s management team has brought a research technology toward commercialization in arelatively short timeframe while also negotiating beneficial license agreements. The Company’s Scientific Advisory Board (SAB) includes leaders in the global cancer marker field. Patents in over 20 countries. Granted patents in the USA, the European Union, Russia and China.

Company Documents
Executive Informational Overview (.pdf)
Letter to Shareholders (.pdf)


Technical Analysis ( Click chart to enlarge )



Sometimes one gets a second chance to buy-in at the beginning of a Bullish reversal. BOCX is giving buyers just this chance. This past month saw a significant (over 500%) gain in share price which expanded the price channel that had been in control since the beginning of this year. Typically, one doubles the height of the previous channel and this indicates the new channel (Blue lines on the chart) reaches up to .32 cents at the top trend-line. Interestingly, on Friday (October 23), the price actually opened on the new mid-line (dashed Blue line on the chart) and gave further proof the expanded channel is now in control. A quick Fibonacci Analysis of the September gain (in Pink on the chart) reveals some very interesting details. The most interesting is that the price can easily reach the top of the channel that sits just below the dependable 123.6% retracement level. Also, the price looks to have consolidated and has breached the 38.2% retracement area turning it into a level of support at .14 cents. That’s exactly where the stock price closed on Friday giving buyers an opportunity. There are numerous bullish indicators to support the probability this stock will continue to climb up the channel. Just this week, the classic Bullish signal of the daily 100 SMA (Orange line on the chart) crossing up and over the daily 200 SMA (Yellow line on the chart) occurred. Also, a type of “ladder bottom” candlestick pattern formed (Red circle) signaling a Bullish reversal. This, too, is a classic signal as the shorts close out their positions and take profits. The sellers appear to be loosing control of the consistent downtrend they controlled after the September highs. The big Green candle coming out of the Red circle indicates buyers taking control. Friday, appears to be a last ditch effort by the sellers to push the price down and close their short positions since they realize 38.2% is now support. This could be the second chance to buy before the price moves back to the top of the price channel and beyond. A simple 100% retracement would represent over a 100% gain from the current price level. It’s also good to keep in the back of your mind that last year this stock was trading above .70 cents and that would be close to the same percentage gain the stock price experienced just last month.

———–

Disclosure: Long BOCX

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• Hold onto your VISA!
• Profiting from the 2008 Beijing Olympic Games
• Extreme FDA Trade – ABIO
• Playing With Fire – ARDM (OTC:ARDM)

(Public, PINK:DVME.PK)

MiV Investments profiles Diverse Media Group (PINK:DVME.PK) which has recently made a 50% acquisition of Celebrities in Action, Inc. which has a joint venture with Stan Lee, and has agreed to sign up for the responsibilities in regards to finding high profile celebrities and athletes for their movie roles. It is important to note that Lee’s former company, Marvel Comics, was acquired by Disney for over $4 billion dollars. The current economic situation may be a horror for most businesses, businesses, but the movie industry is expecting a happy ending. Ticket sales this year are up 17.5 percent to $1.7 billion, and attendance has risen nearly 16 percent, according to Media by Numbers, a box-office tracking company. If attendance continues to increase at the same pace it has for the past six weeks, it would amount to the biggest box-office surge in at least two decades. “People seem to be turning to the movies to escape from the daily worries of their professional lives,” Browning, marketing manager for Regal Entertainment, said. “In economic uncertainty, movies are still a relatively inexpensive form of entertainment when you compare it to sporting events, concerts or going out to eat.” Diverse Media Group, Inc. is ranked by the LA Business Journal as the marketing manager for Regal Entertainment, said. “In economic uncertainty, movies are still a relatively inexpensive form of entertainment when you compare it to sporting events, concerts or going out to eat.” Diverse Media Group, Inc. is ranked by the LA Business Journal as the 10th largest among Hollywood’s most influential agencies. The company also represents actors and directors on leading primetime television shows including Lost, 24, House, Bones, Wildfire, Prison Break, Deadwood, NCIS, Criminal Minds, and previously Seventh Heaven, Charmed, One Tree Hill, and Las Vegas. Diverse Media Group is also one of the few small / micro cap companies which is fully OTC pinksheets compliant.

About Diverse Media Group

Diverse Media Group, Inc. is a publicly traded company that operates entertainment services across all platforms of distribution in the emerging digital age. Diverse Media Group, Inc. is the parent company that emerged as an outgrowth of Diverse Talent Group,Inc. (DTG). DTG was incorporated in the year 2000, but has roots going back 27 years as a talent agency representing artists in motion pictures, television, radio, and commercials. DTG is ranked in the top ten among Hollywood’s most influential agencies. Diverse Media Group, Inc. is expanding upon those years of experience to create a multi-tiered organization which creates content, owns and operates distribution channels, and pioneers methods of packaging entertainment products and services.

Recent News


Network Talks Underway to Develop “Momo” into Weekly TV Series

“Momo” executive producers Dimitri Logothetis and Nicholas Celozzi have announced that talks are underway with networks in the U.S. and Canada to develop the project as a weekly series for television. “Momo” is one of six titles for which Diverse Media Group, Inc. has optioned to purchase a 30% interest from Elio Pictures, Ltd.Diverse Media Group CEO Chris Nassif calls the development “a huge step forward in our company’s transition to a complete entertainment and media services provider.”Logothetis and Celozzi have been working for seven years on the life story of infamous mob boss Sam Giancana. After securing the exclusive story rights from Francine Giancana to her father’s life story, they originally set the project up at Warner Bros. and Turner as a mini-series. Logothetis calculates development costs to date at $75,000. With the success of the 60’s-based AMC series “Mad Men,” they decided that “Momo” could also satisfy weekly audience interest in that period of Americana. Giancana was born in 1908 and killed in 1974. Source here

Diverse Media Group Inc. (DVME) Options Six Titles From Elio Pictures

Diverse Media Group Inc. has optioned to purchase a 30% interest in six titles from Elio Pictures. Diverse Founder and CEO Chris Nassif describes the move as an important building block in acquiring a library of titles for distribution both domestically and worldwide. The Company acquired its first television property, “Hometeam,” in 2007. The program is currently airing in syndication in the U.S. and in South Africa. Nassif says, “Our analysis shows a dramatic shift in media metrics. It gives us an opportunity to create a strong business model, distributing a wide variety of titles across a multitude of platforms.”The Elio Pictures titles include “The Lost Angel” (2005) with Judd Nelson and Nicholas Celozzi, “Framed by Seduction” (2004) starring Robert Patrick, “Nightmare Boulevard” (2004) starring Claudia Christian and Corbin Berenson, “7-10 Split” (2007) featuring Tara Reid and Rachel Hunter, and “Senior Skip Day” (2008) with Lea Thompson and Norm MacDonald. The sixth title, “Momo,” is currently in development.The option is being purchased with 25 million shares of Diverse Media Group restricted common stock, valued at $50,000. The Company has until March 30, 2010, to exercise its option for a cash price of an additional $400,000. According to Elio Pictures, “Framed by Seduction,” made for $3.5 million, has earned $10 million alone, worldwide, since its release. business model, distributing a wide variety of titles across a multitude of platforms.”The Elio Pictures titles include “The Lost Angel” (2005) with Judd Nelson and Nicholas Celozzi, “Framed by Seduction” (2004) starring Robert Patrick, “Nightmare Boulevard” (2004) starring Claudia Christian and Corbin Berenson, “7-10 Split” (2007) featuring Tara Reid and Rachel Hunter, and “Senior Skip Day” (2008) with Lea Thompson and Norm MacDonald. The sixth title, “Momo,” is currently in development.The option is being purchased with 25 million shares of Diverse Media Group restricted common stock, valued at $50,000. The Company has until March 30, 2010, to exercise its option for a cash price of an additional $400,000. According to Elio Pictures, “Framed by Seduction,” made for $3.5 million, has earned $10 million alone, worldwide, since its release. Source here

Diverse Media Group Inc. (DVME) Finalizes Joint Venture to Create Celebrity Superhero Franchises

Diverse Media Group Inc. has completed the acquisition of a 50% equity interest in Celebrities in Action, Inc. (“CIA”) in a joint venture to create new superhero character franchises based on real-life Hollywood celebrities. The new characters will be developed with major stars of film, music, television and sports. Plans include original storylines spanning television, film, mobile and home entertainment, videogames, publishing, consumer products and merchandising.Celebrities In Action, Inc. is a vertically integrated entertainment company that develops, produces and distributes proprietary and licensed entertainment content, with a particular focus on animated celebrities.Diverse Media Group purchased 37,500,000 shares of CIA common stock, representing 50% of all authorized shares of Celebrities In Action, Inc. In exchange, Diverse Media Group agreed to assume CIA’s responsibilities in signing up celebrities and/or well-known athletes to participate in the creative joint venture with Stan Lee’s POW! Entertainment, Inc. Diverse Media Group also agreed to issue 20,400 shares of its Series A Preferred Stock to Fordee CA Trust, the majority CIA shareholder, exchanged for the acquisition of California PA Trust, a California business trust owned by Fordee, and Fordee’s release of its option to acquire the 37,500,000 shares of common stock in CIA.

CIA has an existing joint venture with Stan Lee’s POW! Entertainment banner to develop, produce and distribute animated programming, content and merchandise based on the premise of real-life celebrities in competition against characters from other worlds. Diverse Media Group will identify and secure the celebrity participation and Stan Lee will provide the creative vision to shape these novel superhero personas.

Praised as “a legend” worldwide and honored with his own Hasbro “Marvel Legends” action figure, Stan Lee is associated with such breakthrough superhero characters as Spider-Man®, The Incredible Hulk®, The Fantastic Four®, X-Men®, Iron Man® and Daredevil®. He is also recognized as an innovator in creating new media opportunities and revenue streams for the superhero genre. Among his accomplishments, Stan Lee is credited with leading the expansion of Marvel Comics from a small division of a publishing house to a multimedia corporation, and developing his characters into longstanding franchises.

Hollywood talent agent Chris Nassif, founder of Diverse Talent Group and its parent company, Diverse Media Group, Inc., commented, ”Stan Lee has excelled as a visionary, a leader in the global media industry and a creative talent whose complex fictional characters have become living, breathing members of our world. We are delighted to provide the setting for him to create characters based on real stars, which taps into the resources of CIA, POW! Entertainment, and Diverse Media Group.”

Lee’s POW! Entertainment company has a first-look deal with Disney, which last month acquired his former company, Marvel comics, for $4 Billion. Source here

Represented Actors and Directors on Primetime Shows

Diverse Talent Group represents actors and directors on leading primetime television shows including Lost, 24, House, Bones, Wildfire, Prison Break, Deadwood, NCIS, Criminal Minds, and previously Seventh Heaven, Charmed, One Tree Hill, and Las Vegas. He also has negotiated deals for soap stars on leading daytime shows such as The Young and the Restless, General Hospital and Days of Our Lives. Diverse Talent Group clients have also booked lead roles in feature films such as Dreamgirls, Welcome to America, The Flock and Transformers. clients have also booked lead roles in feature films such as Dreamgirls, Welcome to America, The Flock and Transformers. Source here

Experienced Leadership

Building on a senior leadership group with a combined experience in the entertainment industry of over 100 years, Diverse Media Group Inc. is currently assembling an expanded team of dynamic professionals to help move the Company forward.

CHRIS NASSIF

Chairman & Director
CEO, Diverse Talent Group, Inc. (DTG)

The Company is led by founder Chris Nassif, an agent in the entertainment industry for the past 27 years.  During that time he has represented actors, directors, producers, editors, and has packaged many television and feature film projects. The wide-ranging relationships he has developed with in the Hollywood community are a key asset in the expansion effort.

Read more

STEPHEN J. COHEN

CEO, Director
President, Diverse Television & Syndication

Steve Cohen brings Diverse Media Group a vision honed during a career at the forefront of emerging media platforms. Previously president of Hometeam LLC, a Seattle-based company which received millions in private investment, he also has served as consultant for the launch of the entrepreneur-funded Dyson News Network (DNN).

Read more

RICK FRIEDMAN

Chief Operating Officer
President, Diverse Digital Studios

As Chief Operating Officer , Rick Friedman guides the day-to day business affairs of Diverse Media Group, Inc. (PINK SHEETS: DVME). As president of the company’s new operating division, Diverse Digital Studios, he oversees the development and creation of the company’s new digital products and services.Read more

Industry Forecast

In its newest industry forecast, published August, 3, 2009, Veronis Suhler Stevenson (VSS), a leading private equity firm, predicts that total spending in DVME’s sector of the economy will grow 3.6% per year over the next five years. In fact, VSS forecasts that the next five years will see the sector increase 20% greater than Nominal GDP which will only increase annually 3.0% by 2013. Source here, 2009Q2

Technical Analysis ( Click image to enlarge )

DVME is showing the anticipation to move up in a big way.  The past two months saw a huge 1525% gain in price and a 100% retracement (according to the Fibonacci Analysis in Pink on the chart). For the past two weeks, this stock seems to have been consolidating after this big movement in price. It now appears the consolidation may be complete (Red circle on the chart). Today, the price cleared and closed above a line of resistance/support at the .001 cent level (Orange dashed line). The price also breached the 23.6% retracement level and a closely corresponding ¼ level trend-line of the current price channel (Blue lines on the chart).  Also, the volume (Grey bars) is increasing (along with the price) indicating that there is a positive consensus among traders to support the probability of moving up the price channel.  There is plenty of upside potential and once the price clears the 23.6% level, it appears the 50% level is an easy target. That represents over a 100% gain from today’s closing price. It’s good to keep in the back of your mind that the last time the price cleared this 50% level area, also the middle trend-line of the price channel (Blue dashed line),  the price quickly moved to the top of the current price channel at .0045 cents.  That would mean almost a 250% gain from the current price level.

Overall Sentiment

With a set core group of experienced leadership, an optimistic industry forecast full of growth and opportunities, and the partnership with one of the entertainment industry’s biggest names in Stan Lee — Diverse Media Group should have the ability to breakthrough and set new highs in terms of both business opportunities and financial success. A new star is born.

———–

Disclosure: Long DVME

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• A Renewed Sense of Optimism in Paradigm Medical (OTC:PDMI.PK)
• Profiting from the 2008 Beijing Olympic Games
• $50 in Free Trades for New Sign ups: Questrade Coupon
• Antigenics is a buy – Brain Tumour FDA

XTEND MEDICAL CORP

(Public, PINK:XMDC)

Cancer has quickly become one of the deadliest diseases, causing well over 13% of all human deaths. Cancer rates could further increase by 50% to 15 million new cases in the year 2020, according to the World Cancer Report, the most comprehensive global examination of the disease to date. Due to this emerging need for cancer detection medical devices, new and innovative technologies are bound to step foot within the coming years, in what could potentially be one of the biggest markets of our era. Xtend Medical (PINK:XMDC) is set to partner up with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The merger is expected to be completed 30 to 60 days post the October 1st, 2009 press release.  BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. It is an hand-held, lightweight, portable, and affordable device which has tested for 100% no-false positives, and 95.9% cancer positive . With the U.S. National Science Foundation predicting that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years — XTend, and other medical nanotechnology devices should begin to receive a lot more praise, including the likes of NASA, which has already developed a nanotechnology-based biosensor which helps detect biohazards. “If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we’ve received, the company’s market cap will be substantial,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.

About XTend Medical

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.

Software

The software used in the BioHarp device is a Windows based, 3D imaging program that directs the users to specific points in the body for examination. As you can see from the following slides, this software  pinpoints the readings from the BioHarp and gives the physician or tech a full reading for further treatment of the areas scanned.

The software incorporates the details needed for the proper sales functions to major healthcare companies. By requesting specific patient data as well as any corresponding medical record numbers, the integration into the databases for internal EHR (Electronic Health Records) that current healthcare companies are embracing for patient care.

*Click image to enlarge

BioHarp UNI US Product

BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body’s organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases.  This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.

The unit itself combines with state-of-the-art software developed specifically to assimilate and deliver the results from the 1 or  5-sensor “wand” that scans the body and sends the data for review by a licensed physician, physician’s assistant, or registered nurse for possible further testing or to define the proper course of treatment.

Unlike CT Scans, MRI’s and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in lowering health costs significantly.

The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.

Clinical Trial Results

A total of 656 measurements were carried out for three weeks on mice including those whose subcutaneous tissue was transplanted with cancer cells. In the initial seven (7) days after the transplantation, correct were 166 out of 190 measurements (87.4%), in which normal, healthy mice were not diagnosed with cancer. The total results were 629 hits out of 656 measurements (95.9%) in the experiment period, in which normal, healthy mice were not diagnosed with cancer. It can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer.

In another experimental example of the invention, the diagnostic device of the invention was used to diagnose cancer in the mice whose abdominal cavity was transplanted with leukemia cells. As a result, 84.7% were diagnosed with cancer in a control group, and the remaining 15.3% were diagnosed with inflammation instead of cancer. In the mice whose abdominal cavity was transplanted with leukemia cells, 93.1% were diagnosed with cancer. In view of the fact that cancer will not be induced in the control group but the group transplanted with cancer has a high probability of cancer, it can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer. Clinical data source here

Moreover, on August 15-17, 2007, BioHarp made its debut at FIME 2007

The world’s medical marketplace, in Miami Beach convention center. Over 150 attendees, including 32 certified MD’s from across the world, were scanned and diagnosed with BioHarp. The product demonstration included a 5 minutes scan of the major organs. In every case, where the volunteer had knowledge of their own medical history, we were able to confirm BioHarp’s readings with 100% success. In other cases, we may identified potential problem areas, the volunteer should have checked out. There was a great deal of buzz at the UnI-Biotech booth, with several attendees returning with their co-workers, friends, and partners.

Extended Potential Target Markets

In addition to the human markets, the BioHarp will be marketed to the pet and equine industries. The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets in order to discover potential harmful conditions that can be treated through nutrition and medications. The ability for the veterinarian to market this as an added service allows them to create an additional revenue stream as well as giving pet owners the ability to monitor their pet’s health and hopefully alleviate costly procedures. The equine industry itself can be very lucrative for the company in the future. The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised. As the BioHarp unit can be deployed to the stables, part of their post exercise routine would be for the trainer or vet to scan the horse upon completion of their workout or race and determine if there is any underlying inflammation that can lead to being sidelined, thereby eliminating the ability to earn money racing. This market alone is global in nature as there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners. The yearling sales at places like Keenland, wherein owners plunk down millions to own a potential Triple Crown winner, would benefit by having a BioHarp scanner available in order to scan potential champions to insure the fitness of the horse and to detect potential problems that could arise in the future. These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company. See source here

Potential Revenues

The revenue model for the BioHarp comes from both the hardware and software sales. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. Naturally, if we have groups that are purchasing thousands of units, we will have a discount structure to these monthly fees. With the patient potential in the millions, our revenue model will be very strong and consistent for years to come. See source here

Patents

*Click image to enlarge

1) BioHarp Software Patent: Link to patent here
United States Patent Application 20090137895
Real-time diagnostic system  employing non-invasive method to analyze electro-magnetic field radiated from a subject and the variation thereof

2) Hardware Sensor Pattern: Link to patent here
USPTO Patent Application 20090182218
Sensor for detecting biological electro-magnetic signal and the diagnostic device using the same.

Experienced Management Team

Sam Lee

Mr. Lee is the brainchild behind the BioHarp unit. Mr. Lee has spent the past 14 years perfecting the nano bio-sensor technology and has worked diligently in the continued development of the sensor units and overall BioHarp product. Mr. Lee holds a BA in Public Administration and has a MA in Animal Physiology and Biochemistry.

Achievement

- Established ‘ UNI BIO-TECH.,INC. ’, Seoul Korea. Jun 19. 2000.

- Established R&D Biological Signal Technology, Calif. U.S.A. Mar 1989.

- R&D Biological Signals

- Analysing Study of the Characteristics of revolutionary Bio-Substances

- Unigue prosessing of Bio-Materials for Nano-Biosensor

- Nano- Biosensor development and Production for Hand-Held Detector.

- R & D of Immune strengthening, Prevention and Treatment of Cancer & related Diseases.

- Ubiquitous, e-Healthcare, Monitoring System

Development

- Early stage disease detector using Nano-Biosensor

- Detection of Biological Signals Non-Invasive, Non-Restrictive Diagnostic method

- New Model Development of prototype, Sep 2008 ~ Jun 2009

- KIMES 2008 participated in International Medical Convention at Seoul Korea, Mar 15. ~ Mar  17. 2008

- FIME 2007 participated in International Medical Convention at Miami U.S.A, Aug 15. ~ Aug 17. 2007

- Development of Biological signals detection device- BIOHARP-Hand held device, Jan 2007 ~ Aug 2007

- KGLP approved laboratory animal pre-clinical experiment For new device which detects of early stage various diseases, Apr 2004 ~ May 2004

- Development of Prototype : Biological signals device of single Sensor and Multi-Sensor’s, Apr 2002 ~ May 2004

* For more information on the CEO, CFO, President and Staff behind BioHarp, visit the company’s website here.

Technical Analysis

* Click image to enlarge

Since the beginning of October, volume for XMDC has been on the rise and experiencing over 900% increases in daily volume!  The monthly volume has jumped almost 600% and October isn’t over yet.  This indicates an enormous interest in this company and its activities as of late.  In response, the price action has started a bullish trend with impressive gains. This comes after spending close to 16 months in the bottom half of a very well-defined price channel. If you’re looking to finally get in at the beginning of a price run, this could be the stock! The key indication, along with the jump in volume (grey bars on the chart), is the price has been testing the top of that long established price channel at .02 cents (red circle on the chart). Today was actually the third time the price had tested that top trend-line this month.  It has been observed numerous times in Technical Analysis that the third time is the charm and usually the price will break the trend-line, turn it into support, and will stay above it.  As predicted, the charm worked and the price broke through the .02 cent line and closed well above it today.  This move shows the price channel has expanded (Blue lines on the chart).  Typically, one doubles the height of the previous channel and this indicates the old top trend-line (dashed Blue line on the chart) is now the new mid-line. This shifts the top trend-line up to the .04 cent level.  More evidence that this new price channel is now in control is that the price actually closed right at the ¾ trend-line today at .03 cents.  All this positive sentiment is backed by the standard bullish signal of the daily 100 SMA (Orange line) moving above the daily 200 SMA (Yellow line).  The bullish signal is further strengthened by both these moving averages currently trending up.  It’s good to keep in the back of your mind that during the month of October 2007, the price of this stock was trading at levels above .10 cents and actually reached up to .39 cents.  That would be a 1200% gain from today’s closing price.

Overall Sentiment

With cancer rates set to increase by 50% to 15 million new cases in 2020, the early detection cancer medical device industry could potentially become one of the largest potential markets of our era. XTend Medical has taken a new approach to solving the need by making a device which is lightweight, portable, affordable, and highly accurate and effective. The BioHarp product tested tested for 100% no-false positives, and 95.9% cancer positive, which in its own right is something to marvel at, without even considering the other variables. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. With the CEO admitting himself that the current market cap of $18M is highly undervalued at these levels, an investment in XTend Medical should seem like a no-brainer.

———–

Disclosure: Long XMDC

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• Online Presentation: Breakthrough Treatment Of Pain (OTC:NPHC)
• Third Time’s A Charm For Nuvo Research (TSE:NRI), (PINK:NRIFF)
• Identifying Fact vs. Fiction on Hermispherx’s Ampligen
• A “double edged” time for investing

(Public, OTC:BZCN.PK)

As the holiday season fast approaches during one of the most hard hit economic times in recent memory, certain discount companies look to profit and gain recognition, differentiating themselves from the pack. One of these such companies is BizAuctions Inc. (OTC:BZCN.PK), which is quickly gaining momentum in a $60B excess inventory liquidation  market. The concept is simple, they offer eBay liquidation services for companies who have excess inventory, returns, and overstock items. Given that eBay is one of those companies which is recession proof, investors should feel a little more confident should they choose to place their eggs in this basket. At first glance, this may seem like a simple concept, however it made them a hefty revenue of $1,340,904 during six months ended June/30/2009, and that’s not too bad for a high growth company worth an estimated $640,000 in market cap. Despite the struggling economy, BizAuctions has continued to decrease operating and net losses, all the while maintaining a revived sense of optimism after eBay (NASDAQ:EBAY) hit their highest level in 10-months and exceeded Wall Street’s forecast. BizAuctions alsoruns a retail clothing store named “Lucky 7’s” which opened at the Chula Vista Center, on May/29/09 next to Macy’s in Chula Vista, CA. It is also important to remember that during the last holiday season in December of 2008, the company’s shares reached a one year high of 0.11 price per share.

About BizAuctions Inc.

Bisections Inc. is a provider of commercial eBay liquidation services for excess inventory, overstock items, and returns for retailers, manufacturers, and distributors. The Company sells from home goods, brand name clothes and electronics. The Company lists the merchandise through software which is integrated and compliant with eBay. Once an auction ends, payment is collected via PayPal or credit card. The Company is providing liquidation services to retailers in California, Arizona, and Colorado, and is in the process of expanding into other states.

Financial Analysis ( Data via company’s financial report )
BizAuctions Sales Listings Increase by 14% for November 2008. BizAuctions, Inc. recently announced that its items listed for sale on eBay during the month of November 2008 increased by 14% over listings posted for October 2008. These items, such as big screen TVs, digital cameras, and other electronics, included excess inventory and returned goods which the Company acquired through liquidation projects for its clients. BizAuctions posted 3,586 item listings on eBay for the month of November, which represents an increase of 443 listings.

Operating Expenses for 2008 decreased 5.7% vs 2007 (As a percentage of Gross Revenues)
2007 – $990,940 = 27% of Gross Revenues ($2,771,391)
2008 – $725,124 = 21.3% of Gross Revenues ($3,396,295)

Net Loss for 2008 decreased 17.2% vs 2007 (as a percentage of Gross Revenues)
2007 – $874,403 = 31.8% of Gross Revenues ($2,771,391)
2008 – $494,272 = 14.6% of Gross Revenues ($3,396,295)

As discussed earlier, it is without question that BizAuction’s growth potential is directly dependant and correlational to that of eBay’s. After watching eBay surge to a 10-month high on NASDAQ and exceed Wall Street analyst’s forecast, investors have a bright future to look forward to given that sales and revenues keep up with past trends.

“We feel that there is upside bias to our 2010 estimates in marketplaces and payments. And eBay’s multiple has room to expand as it begins to string together additional signs of platform improvements,” wrote Stepehen Ju of RBC Capital, who upgraded the shares to a buy rating. Press release found here

Competitors Market Share / PPS Evaluation ( Information via OTCReporter.com )

· Liquidity Services Inc. (LSI) is an online auction marketplace for wholesale, surplus and salvage assets. The Company enables buyers and sellers to transact in an automated online auction environment offering over 500 product categories. NASDAQ:LQDT Recent Price:$7.45

· Overstock.com, Inc. is an online closeout retailer offering discount brand name merchandise, including bed-and-bath goods, home decor, kitchenware, watches, jewelry, electronics and computers, sporting goods, apparel, and designer accessories, among other products. It operates as part of its Website an online auction site, a marketplace for the buying and selling of goods and services. AMEX:OSTK Recent Price: $9.35

· Big Lots, Inc. through its wholly owned subsidiaries is a national broadline closeout retailer. As of February 2, 2008, the Company operated a total of 1,353 stores in 47 states. The Company’s merchandising categories include Consumables, Home, Furniture, Seasonal, and Other. The Consumables category includes food, health and beauty, plastics, paper and pet departments. NYSE:BIG Recent Price: $13.48

Technical Analysis ( Click chart to enlarge )

BZCN produced another big green candle and may have started to move up in a big way leaving the “bottom” behind.  The past six months this stock has seen explosive moves while it has been moving through a well defined price channel (Blue lines on the chart). The price has remained in the bottom half of the channel, below the middle trend-line (blue dotted line) for most of this time. It appears the price has finally consolidated after the last visit to the top trend-line back in June. The ¼ trend-line doesn’t appear to be a strong level of resistance.  So, a move above this line would verify the Bullish break-out and the price should easily reach the middle trend-line around .0032 cents and beyond. The upside potential is very large and given the heavy volume (Gray bars on the chart) under the strong green candles these past two days the momentum appears high and the risk low.  It’s good to keep in the back of your mind that earlier this year, before the market fell to the March low, this stock was trading up to .06 cents. That’s a 3900% gain from the closing price on Thursday, October 15th.

Overall Sentiment

As the economic recession continues to plague the United States of America, companies seek new and innovative ways to survive, and in some cases even increase their potential revenues. With the upcoming holiday season fast approaching, BizAuctions Inc. is one of those small companies which should reap the benefits, gain new customers and thus restablish a renewed sense of optimism from investors. Revenue of $1,340,904 during six months ended June 30 2009, and a highly undervalued estimated $640M market cap compared to other competitors should trigger some technical buy signals accross the board. The company also seems to be working to update their software to a more effective and user-friendly platform on their eBay listings, which is always a good thing.

———–

Disclosure: Long BZCN

By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• FDA Play: Soligenix, Poised for a Stellar Comeback (OTC:SNGX.OB)
• A New Spotlight on Diverse Media Group (PINK:DVME.PK)
• An Everlasting Milestone – Thank You
• Burning the Calories with CardioCor (PINK:CDOI.PK)

(Public, OTC:AVXT.PK)

AVAX Technologies, Inc. has gone through a vast number of ups and downs throughout 2006 to 2007. At this time StocksHaven Investments profiles the company and takes look at what investors may expect within the near future.

AVAX had a number of expectations to meet in order to sustain ongoing business operations: equity financing, FDA registration for phase II and phase III clinical trials, and collaborations and expansions.The successful completion of these goals has paved the way for a fresh and optimistic 2008 and thus 2009 for AVAX. Having raised $10M in equity financing, and $1.2M in a collaboration of CTCA on the OVARIAN trials (Ovax), dilution should be out of the question for the remainder of 2010. Despite all of this, there remains one main reason which makes AVAX a solid company: their pipeline which targets some of the fastest growing markets within the biotech medical industry. MVax is aiming towards a $775M Melanoma treatment market by 2010, while Ovax looks to enter a potential Ovarian cancer drug market of $1.6B by 2016. Moreover, AVAX’ currently trades at a highly undervalued estimated market cap of 27.10M when comparred to a similar cancer treatment company in Cell Therapeutics (NASDAQ:CTIC), which is sitting at roughly 627.11M market cap without any drugs currently being approved by the FDA. 2010 should prove to be an eventful year for this up and coming rising small cap biotech. MVax® is AVAX’s lead product candidate and it is currently in an International Phase III Registration trial with centers in the U.S., Europe and Israel. To date over 600 patients have been treated with the AC Vaccine Technology.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is an internationally integrated biotechnology company focused on developing and commercializing its AC Vaccine® technology for the treatment of cancer. The AC Vaccine Technology is an immunotherapeutic treatment that educates the patient’s immune system to recognize cancer cells as foreign through the process of haptenization. Haptenization is a re-education of the immune system through a chemical modification of antigens on the cancer cell which allows for the development of an immune response to cancer cells that were previously ignored by the immune system. To produce AVAX’s AC Vaccine cancer cells are obtained from tumors excised during routine surgery. These cells are then treated with the hapten dinitrophenyl (DNP). Injection of the DNP-modified vaccine induces an immune response against native cancer cells in the patient’s body, and, under the best of circumstances, kills them or controls their growth.

AVAX is headquartered in Philadelphia, PA with operations in Lyon, France where it has established a cGMP manufacturing facility that is currently producing the vaccines for the ongoing Phase III Registration trial of MVax®, the AC Vaccine for Melanoma.

*All information provided from the company’s website at http://www.avax-tech.com

AVAX is an internationally integrated development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. Their vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (“haptenized”) to make them more visible to the patient’s immune system. AVAX refers to their cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine.

The AC Vaccine is processed directly from the patients tumor. The tumor is broken down to the basic cancer cells. These cancer cells undergo a series of treatment steps and then the cells are modified with DNP, which attaches to the proteins on the surface of the cells. These DNP modified tumor cells are then re-administered to the patients with adjuvants in accordance with the previously optimized schedule of vaccine administration.

MVax^® for the Treatment of Melanoma

Entering Phase III Study: MVALDI

AVAX has launched an International Phase III Registration trial entitled “Comparison of MVax® plus Low Dose Interleukin-2 versus Placebo Vaccine plus Low Dose Interleukin-2 in Patients with Stage IV Melanoma”. The study, which has initiated enrollment, is recruiting centers in the U.S., Europe and Israel. The Company will consider adding additional sites and countries as the study progresses.

Registration study enrollment commenced in November 2007. The study is the subject of a Special Protocol Assessment Agreement (SPA) with the U.S. FDA. An SPA is a written agreement between AVAX and the FDA regarding the trial design, surrogate endpoints to be used as a basis of filing for accelerated approval of MVax®, and the statistical analysis plan necessary to support the full regulatory approval of MVax®. An SPA agreement is binding upon the sponsor and the agency.

The Phase III study will enroll up to 387 patients with stage IV melanoma, who will be assigned in a double-blind fashion at a 2:1 ratio to MVax® pt or Placebo vaccine. The MVax® arm will consist of an initial dose of MVax® pt (autologous DNP-modified tumor cells) followed by cyclophosphamide (CY) and then six weekly doses of MVax® administered with Bacillus of Calmette and Guerin (BCG). Following vaccine administration patients will receive a specific schedule of low dose IL-2. Patients assigned to the control group will receive a treatment identical to the MVax® group, except that a Placebo Vaccine will replace MVax®. The primary endpoints of the study are best overall anti-tumor response rate and the percentage of patients surviving at least 2 years. Secondary endpoints of the study will include overall survival time, response duration, percentage complete and partial responses, progression free survival and treatment related adverse events.

The data analysis plan for the study includes an interim analysis of Best Overall Response Rate (complete and partial) to be performed when half the patients (194 patients) have completed assessment of their best anti-tumor response. The comparison of the best overall response rates for the MVax® and control groups will be used as the basis for an expected initial Biologics License Application (BLA) submission under 21 CFR 601 Subpart E, which allows for accelerated approval using a surrogate endpoint in certain life threatening diseases. The analysis of overall survival will be performed when patients have reached the two-year point.

The protocol is based on published data showing that administration of MVax® alone can induce clinically meaningful anti-tumor responses in patients with stage IV melanoma. Moreover, data from other clinical trials and from animal models suggest that the addition of low dose IL2, properly timed, can greatly increase anti-tumor response rates. Finally, because IL2 will be given at a low dose, AVAX expects that its use will not be limited by serious toxicity.

Phase I/II Study Results

AVAX recently announced the successful completion of its Phase I/II study of the treatment of patients with Stage III & IV melanoma. The results of this study will be presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting in Chicago.

The study was designed to evaluate four doses of MVax® with dose defined by the number of cells injected in each vaccine; the doses tested were: 5×106 cells (high dose), 2.5×106 cells (medium dose), 0.5×106 cells (low dose), and 0 cells (zero dose). All dosages were administered according to a previously developed optimum schedule, which included an induction dose without adjuvant followed by low dose cyclophosphamide and then 6 doses admixed with the immunological adjuvant, BCG, Endpoints of the study were safety and an immunological endpoint of delayed-type hypersensitivity (DTH), which is a T-cell-mediated immune response to autologous melanoma cells. The study was also designed to demonstrate that the frozen formulation of MVax® is bio-equivalent to the original, freshly-prepared autologous, hapten-modified vaccine.

The high dose arm of vaccine was highly effective immunologically with positive DTH responses to hapten-modified autologous melanoma cells observed in 22/29 (76%) patients following a course of MVax®; baseline DTH responses were negative, as a condition of enrollment. In contrast, the zero dose arm was ineffective. Linear regression analysis of DTH responses of all evaluable patients showed a clear dose-response relationship when DTH responses for each patient were plotted against the MVax® dose received. These results are important, because previously published studies by AVAX and others showed a statistically significant relationship was seen between survival and induction of DTH after MVax® administration.

The safety profile of MVax® appeared to be very favorable. There were no Serious Adverse Events attributed to MVax®. Non-serious adverse events were similar to what has been observed in previous trials of the autologous, haptenized vaccine: mild-moderate injection site reactions in all patients, mild nausea from cyclophosphamide in some patients, and mild constitutional symptoms, such as fatigue, in some patients after MVax® administration.

LungVax^® for the Treatment of Non Small Cell Lung Cancer

This is the first ever study conducted with the AC Vaccine in the treatment of Non Small Cell Lung Cancer. The study is treating patients with Stage I, II & III disease that undergo complete surgical resection. The vaccine is given to the patients prior to any other post surgical intervention (chemotherapy, etc.).

The study is designed to evaluate three doses of LungVax® with dose defined by the number of cells injected in each vaccine; the doses tested are: 5×106 cells (high dose), 2.5×106 cells (medium dose), and 0.5×106 cells (low dose). All dosages are administered according to a previously developed optimum schedule, which includes an induction dose without adjuvant followed by low dose cyclophosphamide and then 6 doses admixed with the immunological adjuvant, BCG, Endpoints of the study are safety and an immunological endpoint of delayed-type hypersensitivity (DTH), which is a T-cell-mediated immune response to autologous lung cancer cells.

OVax^® for the Treatment of Ovarian Cancer

In data previously presented on the use of OVax®, two phase I-II clinical trials were performed. In the first trial, 9 evaluable patients with newly diagnosed adenocarcinoma of the ovary underwent standard debulking surgery plus six cycles of chemotherapy (taxol + platinum) prior to receiving OVax®. In the second trial, 13 evaluable patients with bulky, chemotherapy-refractory disease were treated. Positive DTH (5-mm induration) to autologous DNP-modified tumor cells was elicited in 19 of 22 patients (median = 14-mm induration). More importantly DTH to unmodified tumor cells was induced in 17 of 22 patients and (median = 6).

Unexpectedly, a clinical responses was observed as well: one patient, who had previously had excision of a peritoneal tumor, exhibited complete regression of a residual peritoneal mass by computed tomography (CT) and a concomitant fall in serum CA-125 from 65 to 6. Both the CT and CA-125 responses were maintained for 6 months.

AVAX intends to activate a Phase I/II IND for the treatment of Stage III & IV Ovarian Cancer patients who have relapsed following chemotherapy. In the planned study, AVAX will evaluate patients for safety and immunological responses, as measured by Delayed Type Hypersensitivity (DTH).

Company Goals and Achievements ( Information from the company’s Fact Sheet [.pdf] )

Technical Chart Analysis ( Click image to enlarge )

The past month for AVXT has been very exciting and signaled a Bullish trend may have just started.  In fact, only three weeks ago, the classic bull signal was given when the 100 day moving average crossed up and over the 200 day moving average.  Currently, both averages are trending upward in bullish fashion. Just today, the price clearly broke a 2-year-old level of resistance around the .15 cent range.  This was the third attempt to break that resistance and, as we have seen numerous times, the third time is the charm. This resistance also corresponded to the top trend-line of a price channel that has been in control since 2007.  This move indicates the price channel has expanded and the previous top trend-line (dashed Blue line) now appears to be the new mid-line.  Typically, one doubles the height of the previous channel and this could indicate the new top trend-line of the expanded channel (Blue lines on the chart) is near the .29 cent level.  Interestingly, the price actually touched the new ¾ trend-line today and gave further proof the expanded channel is now in control.  With so much interest in this company’s activities, as evident by the significant increases in volume (Gray bars on the chart), the stock appears ready to carry on into the upper level of the expanded price channel and beyond.  It’s also good to keep in mind that in the past this stock spent over a year trading at prices well above the top of the newly expanded channel reaching prices above .40 cents.

Overall Sentiment

Having finally managed to find the means for capital in order to fund ongoing research and development costs, all the while establishing stability by joining the OTC market, the company seems to have moved past its most troubled times and onto greener pastures. The end of 2009, and beginning of 2010 should provide a rebirth for AVAX, boosting investor confidence as they begin to focus on the phase II and phase III clinical trials respectively. The results of these trials remains unknown, however, when taking a look at other struggling cancer biotechs which are entering or have entered phase III, it is easy to depict which way this stock and its market cap of 27.10M will go — just take a look at Cell Therapeutics (NASDAQ:CTIC).

———–

Disclosure: Long AVXT.PK

———–

By reading StocksHaven Investments company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

StocksHaven Investments is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Random Posts

• NSPT is a buy
• FDO is a buy 8/4/09
• Are you ready to start Investing?
• Empowering Alternative Renewable Energy from Disposable Waste (PINK:WTWO.PK)